BCL11A rs243021多态性与代谢相关脂肪性肝病易感性的关系
Association of the BCL11A rs243021 Polymorphism with Susceptibility to Metabolic Dysfunction-Associated Fatty Liver Disease
DOI: 10.12677/acm.2025.15123624, PDF,   
作者: 孟 馨:青岛大学青岛市市立医院感染性疾病科,山东 青岛;青岛大学青岛医学院,山东 青岛;赵真真*:青岛大学青岛市市立医院临床研究中心,山东 青岛
关键词: 代谢相关脂肪性肝病B细胞淋巴瘤/白血病11A基因多态性Metabolic Dysfunction-Associated Fatty Liver Disease B-Cell Lymphoma/Leukemia 11A Gene Polymorphism
摘要: 目的:探讨中国青岛地区B细胞淋巴瘤/白血病11A (BCL11A)基因rs243021位点多态性与代谢相关脂肪性肝病(MAFLD)疾病易感性的关系。方法:纳入于青岛市市立医院就诊的MAFLD患者215例、健康对照159例,收集所有受试者的临床信息和生化指标,进行生化指标的临床检测及基因组DNA的提取和BCL11A rs243021位点基因型测定。计数资料比较采用Pearson χ2检验,计量资料根据其符合正态分布与否分别采用独立样本t检验或Wilcoxon秩和检验。应用非条件logistic回归模型进行位点多态性与疾病风险分析。结果:MAFLD组和健康对照组之间比较BCL11A rs243021位点的基因型分布和等位基因分布差异均无统计学意义(P > 0.05)。在A等位基因携带者与非携带者之间进行比较,各临床资料和实验室指标差异均无统计学意义(P > 0.05)。结论:青岛地区汉族人群中BCL11A rs243021多态性与MAFLD易感性无显著相关。
Abstract: Objective: To investigate the association between the B-cell lymphoma/leukemia 11A(BCL11A) rs243021 polymorphism and susceptibility to metabolic dysfunction-associated fatty liver disease (MAFLD) in the Qingdao region of China. Methods: A total of 215 MAFLD patients and 159 healthy controls were recruited from Qingdao Municipal Hospital. Demographic and laboratory data were recorded for all subjects. Clinical biochemical testing, genomic DNA extraction, and genotyping of the BCL11A rs243021 locus were conducted. Categorical variables were compared using Pearson’s chi-square test, while continuous variables were tested for normality and then compared by either an independent samples t-test or a Wilcoxon rank-sum test, as appropriate. Unconditional logistic regression models were used to analyze the association between genetic polymorphisms and disease risk. Results: There were no significant differences in genotype or allele frequencies between the MAFLD and control groups (both P > 0.05). When comparing carriers and non-carriers of the A allele, no statistically significant differences were observed in clinical and laboratory parameters (both P > 0.05). Conclusion: In the Han Chinese population of Qingdao, the BCL11A rs243021 polymorphism was not significantly associated with MAFLD susceptibility.
文章引用:孟馨, 赵真真. BCL11A rs243021多态性与代谢相关脂肪性肝病易感性的关系[J]. 临床医学进展, 2025, 15(12): 2038-2046. https://doi.org/10.12677/acm.2025.15123624

参考文献

[1] Eslam, M., Sanyal, A.J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., et al. (2020) MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 158, 1999-2014.e1. [Google Scholar] [CrossRef] [PubMed]
[2] Chalasani, N., Younossi, Z., Lavine, J.E., Charlton, M., Cusi, K., Rinella, M., et al. (2018) The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 67, 328-357. [Google Scholar] [CrossRef] [PubMed]
[3] Habibullah, M., Jemmieh, K., Ouda, A., Haider, M.Z., Malki, M.I. and Elzouki, A. (2024) Metabolic-Associated Fatty Liver Disease: A Selective Review of Pathogenesis, Diagnostic Approaches, and Therapeutic Strategies. Frontiers in Medicine, 11, Article ID: 1291501. [Google Scholar] [CrossRef] [PubMed]
[4] Amini-Salehi, E., Letafatkar, N., Norouzi, N., Joukar, F., Habibi, A., Javid, M., et al. (2024) Global Prevalence of Nonalcoholic Fatty Liver Disease: An Updated Review Meta-Analysis Comprising a Population of 78 Million from 38 Countries. Archives of Medical Research, 55, Article 103043. [Google Scholar] [CrossRef] [PubMed]
[5] Wu, Y., Zheng, Q., Zou, B., Yeo, Y.H., Li, X., Li, J., et al. (2020) The Epidemiology of NAFLD in Mainland China with Analysis by Adjusted Gross Regional Domestic Product: A Meta-Analysis. Hepatology International, 14, 259-269. [Google Scholar] [CrossRef] [PubMed]
[6] Streba, L.A.M., Vere, C., Rogoveanu, I., et al. (2015) Nonalcoholic Fatty Liver Disease, Metabolic Risk Factors, and Hepatocellular Carcinoma: An Open Question. World Journal of Gastroenterology, 21, 4103-4110. [Google Scholar] [CrossRef] [PubMed]
[7] Teng, T., Qiu, S., Zhao, Y., Zhao, S., Sun, D., Hou, L., et al. (2022) Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 23, Article 7841. [Google Scholar] [CrossRef] [PubMed]
[8] Moretti, V., Romeo, S. and Valenti, L. (2024) The Contribution of Genetics and Epigenetics to MAFLD Susceptibility. Hepatology International, 18, 848-860. [Google Scholar] [CrossRef] [PubMed]
[9] Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B.G., Zhou, H.H., Tybjærg-Hansen, A., et al. (2014) Exome-Wide Association Study Identifies a TM6SF2 Variant that Confers Susceptibility to Nonalcoholic Fatty Liver Disease. Nature Genetics, 46, 352-356. [Google Scholar] [CrossRef] [PubMed]
[10] Chen, Y., Du, X., Kuppa, A., Feitosa, M.F., Bielak, L.F., O’Connell, J.R., et al. (2023) Genome-Wide Association Meta-Analysis Identifies 17 Loci Associated with Nonalcoholic Fatty Liver Disease. Nature Genetics, 55, 1640-1650. [Google Scholar] [CrossRef] [PubMed]
[11] Chen, V.L., Kuppa, A., Oliveri, A., Chen, Y., Ponnandy, P., Patel, P.B., et al. (2025) Human Genetics of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Variants to Cause to Precision Treatment. Journal of Clinical Investigation, 135, e186424. [Google Scholar] [CrossRef] [PubMed]
[12] Satterwhite, E., Sonoki, T., Willis, T.G., Harder, L., Nowak, R., Arriola, E.L., et al. (2001) The BCL11 Gene Family: Involvement of BCL11A in Lymphoid Malignancies. Blood, 98, 3413-3420. [Google Scholar] [CrossRef] [PubMed]
[13] Huang, P., Peslak, S.A., Ren, R., Khandros, E., Qin, K., Keller, C.A., et al. (2022) HIC2 Controls Developmental Hemoglobin Switching by Repressing BCL11A Transcription. Nature Genetics, 54, 1417-1426. [Google Scholar] [CrossRef] [PubMed]
[14] Yin, J., Xie, X., Ye, Y., Wang, L. and Che, F. (2019) BCL11A: A Potential Diagnostic Biomarker and Therapeutic Target in Human Diseases. Bioscience Reports, 39, BSR20190604. [Google Scholar] [CrossRef] [PubMed]
[15] Peiris, H., Park, S., Louis, S., Gu, X., Lam, J.Y., Asplund, O., et al. (2018) Discovering Human Diabetes-Risk Gene Function with Genetics and Physiological Assays. Nature Communications, 9, Article No. 3855. [Google Scholar] [CrossRef] [PubMed]
[16] 范建高, 徐小元, 南月敏, 等. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版) [J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[17] Godoy-Matos, A.F., Silva Júnior, W.S. and Valerio, C.M. (2020) NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes. Diabetology & Metabolic Syndrome, 12, Article No. 60. [Google Scholar] [CrossRef] [PubMed]
[18] Sakurai, Y., Kubota, N., Yamauchi, T. and Kadowaki, T. (2021) Role of Insulin Resistance in MAFLD. International Journal of Molecular Sciences, 22, Article 4156. [Google Scholar] [CrossRef] [PubMed]
[19] Carlsson, B., Lindén, D., Brolén, G., Liljeblad, M., Bjursell, M., Romeo, S., et al. (2020) Review Article: The Emerging Role of Genetics in Precision Medicine for Patients with Non‐Alcoholic Steatohepatitis. Alimentary Pharmacology & Therapeutics, 51, 1305-1320. [Google Scholar] [CrossRef] [PubMed]
[20] Shang, S., Li, X., Azzo, A., Truong, T., Dozmorov, M., Lyons, C., et al. (2023) MBD2a-NuRD Binds to the Methylated Γ-Globin Gene Promoter and Uniquely Forms a Complex Required for Silencing of HbF Expression. Proceedings of the National Academy of Sciences, 120, e2302254120. [Google Scholar] [CrossRef] [PubMed]
[21] Horton, J.R., Yu, M., Zhou, J., Tran, M., Anakal, R.R., Lu, Y., et al. (2025) Multimeric Transcription Factor BCL11A Utilizes Two Zinc-Finger Tandem Arrays to Bind Clustered Short Sequence Motifs. Nature Communications, 16, Article No. 3672. [Google Scholar] [CrossRef] [PubMed]
[22] 陈艳敏, 杜诗蓓, 金倩涯, 等. BCL11A基因在实体肿瘤恶性进程中的研究进展[J]. 中华转移性肿瘤杂志, 2021, 4(1): 66-69.
[23] Simonis-Bik, A.M., Nijpels, G., van Haeften, T.W., Houwing-Duistermaat, J.J., Boomsma, D.I., Reiling, E., et al. (2009) Gene Variants in the Novel Type 2 Diabetes Loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B Affect Different Aspects of Pancreatic β-Cell Function. Diabetes, 59, 293-301. [Google Scholar] [CrossRef] [PubMed]
[24] Liang, F., Kume, S. and Koya, D. (2009) SIRT1 and Insulin Resistance. Nature Reviews Endocrinology, 5, 367-373. [Google Scholar] [CrossRef] [PubMed]
[25] Hebbar, P., Abubaker, J.A., Abu-Farha, M., Tuomilehto, J., Al-Mulla, F. and Thanaraj, T.A. (2019) A Perception on Genome-Wide Genetic Analysis of Metabolic Traits in Arab Populations. Frontiers in Endocrinology, 10, Article ID: 8. [Google Scholar] [CrossRef] [PubMed]
[26] Jonsson, A., Ladenvall, C., Ahluwalia, T.S., Kravic, J., Krus, U., Taneera, J., et al. (2013) Effects of Common Genetic Variants Associated with Type 2 Diabetes and Glycemic Traits on α-and β-Cell Function and Insulin Action in Humans. Diabetes, 62, 2978-2983. [Google Scholar] [CrossRef] [PubMed]
[27] Tang, L., Wang, L., Ye, H., Xu, X., Hong, Q., Wang, H., et al. (2014) BCL11A Gene DNA Methylation Contributes to the Risk of Type 2 Diabetes in Males. Experimental and Therapeutic Medicine, 8, 459-463. [Google Scholar] [CrossRef] [PubMed]
[28] Benitez, C.M., Qu, K., Sugiyama, T., Pauerstein, P.T., Liu, Y., Tsai, J., et al. (2014) An Integrated Cell Purification and Genomics Strategy Reveals Multiple Regulators of Pancreas Development. PLOS Genetics, 10, e1004645. [Google Scholar] [CrossRef] [PubMed]
[29] Voight, B.F., Scott, L.J., Steinthorsdottir, V., Morris, A.P., Dina, C., Welch, R.P., et al. (2010) Twelve Type 2 Diabetes Susceptibility Loci Identified through Large-Scale Association Analysis. Nature Genetics, 42, 579-589. [Google Scholar] [CrossRef] [PubMed]
[30] Wang, M., Zhao, Y., He, Y., Zhang, L., Liu, J., Zheng, S., et al. (2023) The Bidirectional Relationship between NAFLD and Type 2 Diabetes: A Prospective Population-Based Cohort Study. Nutrition, Metabolism and Cardiovascular Diseases, 33, 1521-1528. [Google Scholar] [CrossRef] [PubMed]
[31] Cernea, S. (2024) NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic-Metabolic Interplay. Life, 14, Article 272. [Google Scholar] [CrossRef] [PubMed]
[32] Marušić, M., Paić, M., Knobloch, M. and Liberati Pršo, A. (2021) NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. Canadian Journal of Gastroenterology and Hepatology, 2021, Article ID: 6613827. [Google Scholar] [CrossRef] [PubMed]
[33] Younossi, Z.M., Golabi, P., de Avila, L., Paik, J.M., Srishord, M., Fukui, N., et al. (2019) The Global Epidemiology of NAFLD and NASH in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Journal of Hepatology, 71, 793-801. [Google Scholar] [CrossRef] [PubMed]
[34] Mantovani, A., Petracca, G., Beatrice, G., Tilg, H., Byrne, C.D. and Targher, G. (2020) Non-Alcoholic Fatty Liver Disease and Risk of Incident Diabetes Mellitus: An Updated Meta-Analysis of 501 022 Adult Individuals. Gut, 70, 962-969. [Google Scholar] [CrossRef] [PubMed]
[35] Maurano, M.T., Humbert, R., Rynes, E., Thurman, R.E., Haugen, E., Wang, H., et al. (2012) Systematic Localization of Common Disease-Associated Variation in Regulatory DNA. Science, 337, 1190-1195. [Google Scholar] [CrossRef] [PubMed]
[36] Matthew, T., Richard Humbert, E., Robert, E., et al. (2020) The GTEx Consortium Atlas of Genetic Regulatory Effects across Human Tissues. Science, 369, 1318-1330.